Perflutren, a diagnostic drug that is intended to be used for contrast enhancement during the indicated echocardiographic procedures, is comprised of lipid-coated microspheres filled with octafluoropropane(OFP) gas. When exposed to ultrasound waves, the microspheres resonate and "echo" strong signals back to the ultrasound machine. The difference in density between the gas-filled bubbles and the blood around them creates an increased level of contrast visible in the resulting ultrasound image. During echocardiography, activated Perflutren enhances images of the inner edges or borders of the heart, producing an improved image that may enable physicians to better diagnose patients.
Used as an ultrasound contrast imaging in cardiology and radiology.
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
Mayo Clinic in Florida, Jacksonville, Florida, United States
Mayo Clinic in Rochester, Rochester, Minnesota, United States
University of Washington Harborview Medical Center, Seattle, Washington, United States
Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
Mayo Clinic, Rochester, Minnesota, United States
Thomas Jefferson University, Philadelphia, Pennsylvania, United States
Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
Los Angeles County-USC Medical Center, Los Angeles, California, United States
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
Amsterdam Medical Center, Amsterdam-Zuidoost, Netherlands
Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States
Mayo Clinic Minnesota, Rochester, Minnesota, United States
Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
Mayo Clinic in Rochester, Rochester, Minnesota, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.